|Awarded On||February 16, 2022|
|Title||MiR223-3p Suppression of BRCA1-Mutant Oncogenesis|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Robert Hromas|
|Cancer Sites||Breast, Ovary|
All cells, including cancers, must replicate their DNA to divide. DNA replication is not a smooth process, but one filled with stops that must be overcome. The preferred pathway to restart DNA replication is called homologous recombination (HR), which preserves the genetic code. There is a back-up restart pathway called alternative non-homologous end joining (aNHEJ), but this pathway does not always preserve genetic information and can cause chromosomal abnormalities called translocations. These chromosomal translocations can lead to cell death, cell aging, or transformation to malignancy.
Normal cells express a small RNA segment termed miR223-3p that represses aNHEJ and promotes HR. When a...